SCHEMBL29397237

SCHEMBL29397237

Cc1ccc(C)c(C=O)c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 5/20 0.42
PADI4 Q9UM07 1/20 0.41
ERN1 O75460 7/20 0.40
KDM4E B2RXH2 3/20 0.37
HPGD P15428 3/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
KMT2A Q03164 2/20 0.37
AOX1 Q06278 1/20 0.37
TRPA1 O75762 1/20 0.37
ALB P02768 2/20 0.37
USP2 O75604 2/20 0.37
TRIM24 O15164 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
HSD17B10 Q99714 2/20 0.36
NPC1 O15118 1/20 0.36
LDHA P00338 1/20 0.36
ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3966986 1.00 CYP3A4 (0.42) CYP3A4MAPTALDH1A1PADI4ERN1
SCHEMBL841552 0.86 CYP3A4 (0.48) CYP3A4MAPTALDH1A1PADI4ERN1
SCHEMBL14577383 0.86 ERN1 (0.46) CYP3A4MAPTALDH1A1PADI4ERN1
SCHEMBL4650198 0.86 CYP3A4 (0.44) CYP3A4MAPTALDH1A1PADI4ERN1
SCHEMBL4580995 0.84 ERN1 (0.45) CYP3A4MAPTALDH1A1PADI4ERN1
SCHEMBL25322018 0.82 ALDH1A1 (0.46) CYP3A4MAPTALDH1A1PADI4ERN1
SCHEMBL1678780 0.82 ERN1 (0.48) CYP3A4MAPTALDH1A1PADI4ERN1
SCHEMBL1678698 0.82 ALDH1A1 (0.41) CYP3A4MAPTALDH1A1PADI4ERN1
SCHEMBL16346300 0.82 ERN1 (0.50) CYP3A4MAPTALDH1A1PADI4ERN1
SCHEMBL29955992 0.82 ALDH1A1 (0.41) CYP3A4MAPTALDH1A1PADI4ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120117968-A Process for preparing hydroxy-ortho-hydroxymethyl substituted methylene bridged substituted phenols and polyphenols containing multiple phenol units 天津久日半导体材料有限公司 2025-06-10 CN disclosed
CN-113950476-B Substituted 4- [5- (benzofuran-2-yl) -1,2, 4-oxadiazol-3-yl ] benzoic acid compounds for the treatment of neuropathic pain 伦敦皇家学院 2024-08-16 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11401265-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists KING'S COLLEGE LONDON 2022-08-02 US disclosed
CN-109415356-B Crystalline forms of 4- (5- (4, 7-dimethylbenzofuran-2-yl) -1,2, 4-oxadiazol-3-yl) benzoic acid and methods for their preparation 伦敦皇家学院 2022-03-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11401265-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists RARB, RARA, RXRB CYP3A4 2756/4885MAPT 2234/4885ALDH1A1 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.